Expression of four cancer-testis antigens in TNBC indicating potential universal immunotherapeutic targets,Journal of Cancer Research and Clinical Oncology

当前位置： X-MOL 学术 › J. Cancer Res. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Expression of four cancer-testis antigens in TNBC indicating potential universal immunotherapeutic targets
Journal of Cancer Research and Clinical Oncology ( IF 2.7 ) Pub Date : 2023-08-23 , DOI: 10.1007/s00432-023-05274-0
Jie Xiao ₁ , Fengli Huang ₂ , Lin Li ₃ , Lianru Zhang ₁ , Li Xie ₁ , Baorui Liu ₁

Affiliation

Objective

Immunotherapy is an attractive treatment for breast cancer. Cancer-testis antigens (CTAs) are potential targets for immunotherapy for their restricted expression. Here, we investigate the expression of CTAs in breast cancer and their value for prognosis. So as to hunt for a potential panel of CTAs for universal immunotherapeutic targets.

Material and methods

A total of 137 breast cancer tissue specimens including 51 triple-negative breast cancer (TNBC) were assessed for MAGE-A4, MAGEA1, NY-ESO-1, KK-LC-1 and PRAME expression by immunohistochemistry. The expression of PD-L1 and TILs was also calculated and correlated with the five CTAs. Clinical data were collected to evaluate the CTA’s value for prognosis. Data from the K-M plotter were used as a validation cohort.

Results

The expression of MAGE-A4, NY-ESO-1 and KK-LC-1 in TNBC was significantly higher than in non-TNBC (P = 0.012, P = 0.005, P < 0.001 respectively). 76.47% of TNBC expressed at least one of the five CTAs. Patients with positive expression of either MAGE-A4 or PRAME had a significantly extended disease-free survival (DFS). Data from the Kaplan–Meier plotter confirm our findings.

Conclusions

MAGE-A4, NY-ESO-1, PRAME and KK-LC-1 are overexpressed in breast cancer, especially in TNBC. Positive expression of MAGE-A4 or PARME may be associated with prolonged DFS. A panel of CTAs is attractive universal targets for immunotherapy.

中文翻译：

TNBC 中四种癌睾丸抗原的表达表明潜在的通用免疫治疗靶点

客观的

免疫疗法是一种有吸引力的乳腺癌治疗方法。癌症睾丸抗原（CTA）因其表达受限而成为免疫治疗的潜在靶标。在这里，我们研究了 CTA 在乳腺癌中的表达及其对预后的价值。从而寻找潜在的通用免疫治疗靶点的CTA组。

材料与方法

通过免疫组织化学方法评估了总共 137 例乳腺癌组织标本，包括 51 例三阴性乳腺癌 (TNBC) 的 MAGE-A4、MAGEA1、NY-ESO-1、KK-LC-1 和 PRAME 表达。还计算了 PD-L1 和 TIL 的表达，并与五个 CTA 相关。收集临床数据来评估 CTA 对预后的价值。来自 KM 绘图仪的数据被用作验证队列。

结果

TNBC 中 MAGE-A4、NY-ESO-1 和 KK-LC-1 的表达显着高于非 TNBC（分别为P = 0.012、P = 0.005、P < 0.001）。76.47% 的 TNBC 表达了五种 CTA 中的至少一种。MAGE-A4 或 PRAME 阳性表达的患者的无病生存期 (DFS) 显着延长。来自卡普兰-迈耶绘图仪的数据证实了我们的发现。